# US 2019/0290745 A1 · Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0290745 A1
- Document ID: US20190290745A1
- Status: Published application
- Kind: A1
- Application number: 16/068,527
- Filed: 2017-01-09
- Published: 2019-09-26
- Earliest claimed: 2016-01-08
- Assignees: GeoVax, Inc.
- Applicants: Geovax Inc.
- Inventors: Harriet Robinson; Arban Domi; Michael Hellerstein; Farshad Guirakhoo; Nathanael Paul McCurley
- Web page: https://patentgrep.com/patent/US20190290745A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12N 15/86: Viral vectors
- A61K 39/00117: {Mucins, e.g. MUC-1}
- A61P 37/04: Immunostimulants
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C12N 7/045: {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- C12N 2710/24123: Virus like particles [VLP]
- C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The compositions and methods are described for generating an immune response to a tumor associated antigen such as MUC1. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a neoplasm expressing the tumor associated antigen in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat neoplasms and associated diseases.

## Claims

### Claim 1

A recombinant modified vaccinia ankara (MVA) viral vector comprising a sequence encoding a TAA sequence or fragment thereof and a matrix protein sequence, wherein both the TAA sequence and matrix protein sequence are under the control of promoters compatible with poxvirus expression systems.

### Claim 2 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence and the matrix protein sequence are inserted into one or more deletion sites of the MVA selected from I, II, III, IV, V or VI.

### Claim 3 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence and the matrix protein sequence are inserted into the MVA in a natural deletion site, a modified natural deletion site, or between essential or non-essential MVA genes.

### Claim 4 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence and the matrix protein sequence are inserted into the same natural deletion site, a modified natural deletion site, or between the same essential or non-essential MVA genes

### Claim 5 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence and the matrix protein sequence are inserted into different natural deletion sites, different modified deletion sites, or between different essential or non-essential MVA genes each under the control of a promoter compatible with poxvirus expression systems.

### Claim 6 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence is inserted between two essential and highly conserved MVA genes; and the matrix protein sequence is inserted into a restructured and modified deletion III.

### Claim 7 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence is inserted between MVA genes, I8R and G1L

### Claim 8 (depends on 1)

The recombinant vector of claim 1, wherein the promoter is selected from the group consisting of Pm2H5, Psyn II, and mH5 promoters or combinations thereof.

### Claim 9 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence is optimized by one or more method selected from: changing selected codons to other synonymous codons that are optimal for protein expression by MVA, interrupting homopolymer stretches using silent mutations, interrupting transcription terminator motifs using silent mutations, or leading to expression of the transmembrane (rather than secreted) form of TAA.

### Claim 10 (depends on 1)

The recombinant vector of claim 1, wherein the recombinant MVA viral vector expresses TAA and matrix proteins that assemble into VLPs.

### Claim 11 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence comprises SEQ ID NO:1 or SEQ ID NO:2.

### Claim 12 (depends on 1)

The recombinant vector of claim 1, wherein the TAA sequence comprises SEQ ID NO:4.

### Claim 13 (depends on 1)

The recombinant vector of claim 1, wherein the vector further comprises an extracellular fragment of MUC-1, an intracellular fragment of MUC-1, and a transmembrane domain of a glycoprotein (GP) of Marburg virus.

### Claim 14

A pharmaceutical composition comprising at least one recombinant MVA vector and a pharmaceutically acceptable carrier, wherein the recombinant MVA vector comprises a TAA sequence, wherein the sequence is under the control of promoters compatible with poxvirus expression systems.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the at least one recombinant MVA vector is formulated for intraperitoneal, intramuscular, intradermal, epidermal, mucosal or intravenous administration.

### Claim 16 (depends on 14)

The pharmaceutical composition of claim 14, wherein the recombinant MVA vector comprises an extracellular fragment of MUC-1, an intracellular fragment of MUC-1, and a transmembrane domain of a glycoprotein (GP) of Marburg virus.

### Claim 17

A method of inducing an immune response in a subject in need thereof, said method comprising administering at least one recombinant MVA vector to the subject in an amount sufficient to induce an immune response,
wherein the recombinant MVA vector comprises a TAA sequence and a matrix protein sequence wherein the sequences are operably linked to promoters compatible with poxvirus expression systems.

### Claim 18 (depends on 17)

The method of claim 17, wherein the immune response is a humoral immune response, a cellular immune response or a combination thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein the immune response comprises production of binding antibodies or neutralizing antibodies against the TAA.

### Claim 20 (depends on 17)

The method of claim 17, wherein the immune response comprises production of non-neutralizing antibodies against the TAA.

### Claim 21 (depends on 17)

The method of claim 17, wherein the immune response comprises production of a cell-mediated immune response against the TAA.

### Claim 22 (depends on 14)

A method of preventing or reducing the growth of a neoplasm comprising administering the composition of claim 14 to a subject in need thereof in an amount sufficient to prevent or reduce the growth of the neoplasm.

### Claim 23 (depends on 14)

A method of treating cancer by administering the composition of claim 14 to a subject in need thereof in an amount sufficient to treat the cancer.
